Business
Plandai Biotechnology Issues Business Targets and Milestones for Remainder of 2018
Plandai Biotechnology Issues Business Targets and Milestones for Remainder of 2018.
About this update from Plandai Biotechnology, Inc.
[{"type":"text","content":"\n\n \n Looking to Ramp Commercialization and Accelerate Revenue Growth LONDON, UNITED KINGDOM, March 20, 2018 (GLOBE NEWSWIRE) -- Plandaí Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandaí”), a producer of nutraceutical and highly phyto-available extracts, today announced business objectives, targets and milestones for the remainder of 2018. Plandaí is excited with the development and progress of its Phytofare® extracts as it delivers a more meaningful and beneficial dose at highly competitive prices to the consumer. The Company has identified and is targeting three industries to accelerate its revenue growth.  First, in 2017, Plandai conducted preliminary investigations and research into developing a Phytogenic feed supplement for use in animal husbandry. This included doing multiple preliminary clinical studies with the aim of improving animal wellness across the broad animal husbandry sector. The results thus far have been outstanding, and the Company is currently working to complete its trials.  When the latest trials are completed and the results made available for release, the company will issue a further press release discussing the findings and the Company’s future plans. Roger Duffield, the Company’s director and Chief Science Officer assigned to the tests, commented: “We are encouraged and excited about the significant potential impact that these results may have across multiple animal related industries.”  Second, the Company has developed targeted nutraceutical supplements to enhance health and wellness for consumers which were launched last year.  After struggling a bit to find its niche, Phytofare® is now finally building in sales momentum.  We have contracts with several large, international nutraceutical customers and developed a private label product with Coyne Healthcare that has been selling well.  Coyne is targeting a major product launch in the United States this year and we are excited to see our shareholders finally have the opportunity to see Phytofare® on the shelves at their local stores.  Finally, last year Plandaí conducted a primate bioavailability study in Mauritius designed to help set target dosage for an upcoming diabetes human clinical trial.  ...